Hear what a Stargardt Macular Degeneration patient in our Clinical Trial has to say about her experience.
Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.

Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
LEARN ABOUT OUR TECHNOLOGY
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.
Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration

Nanoscope News & Events
-
Nanoscope Therapeutics Announces Presentations at the World Orphan Drug CongressMay 22, 2023
-
Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual MeetingApril 27, 2023
-
Nanoscope Therapeutics Announces Presentations at the ARVO Annual MeetingApril 13, 2023
-
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis PigmentosaMarch 30, 2023
-
Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic AdvisorMarch 20, 2023
-
Nanoscope Therapeutics Announces World Health Organization Selection of "Sonpiretigene Isteparvovec" as International Nonproprietary Name for MCO-010February 28, 2023
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing BoardFebruary 13, 2023
-
Nanoscope Therapeutics to Present at the BIO CEO & Investor ConferenceFebruary 2, 2023